Patients outcome. by Loïc Duron (6433634)

“…Reliance on temporal-artery biopsy fell (17% vs 91%; p < 0.01), owing to a four-fold rise in diagnostic MRI use. Mean total medical costs decreased by €814 per patient (€3672 ± 2861 vs €4486 ± 3193), although this difference did not reach statistical significance (p = 0.23).…”

Impact of Cold Plasma Treatment on the Shelf Life and Metabolite Profiles of Strawberries during Storage by D. Abouelenein (22365684)

“…Strawberries are abundant in bioactive compounds and serve as a significant source of ascorbic acid. However, their shelf life is notoriously short due to their high sensitivity to environmental conditions and susceptibility to microbial contamination. …”

Image 2_Soil acidification and nutrient imbalance mediate fungal community degradation, a key driver of continuous cropping obstacles in Platycodon grandiflorus.tif by Li Li (14993)

Image 1_Soil acidification and nutrient imbalance mediate fungal community degradation, a key driver of continuous cropping obstacles in Platycodon grandiflorus.jpeg by Li Li (14993)

Table 1_Soil acidification and nutrient imbalance mediate fungal community degradation, a key driver of continuous cropping obstacles in Platycodon grandiflorus.docx by Li Li (14993)

Table 2_Soil acidification and nutrient imbalance mediate fungal community degradation, a key driver of continuous cropping obstacles in Platycodon grandiflorus.docx by Li Li (14993)

Primers for qPCR. by Kaitao Zhao (3617825)

“…Results revealed the MRE11–RAD50–NBS1 (MRN) complex as a potential factor. Transiently or stably knockdown of MRE11, RAD50 or NBS1 in hepatocytes before HBV infection significantly decreased viral markers, including cccDNA, while reconstitution reversed the effect. …”

Antibodies used for western blotting. by Kaitao Zhao (3617825)

“…Results revealed the MRE11–RAD50–NBS1 (MRN) complex as a potential factor. Transiently or stably knockdown of MRE11, RAD50 or NBS1 in hepatocytes before HBV infection significantly decreased viral markers, including cccDNA, while reconstitution reversed the effect. …”

Target sequences of siRNAs. by Kaitao Zhao (3617825)

“…Results revealed the MRE11–RAD50–NBS1 (MRN) complex as a potential factor. Transiently or stably knockdown of MRE11, RAD50 or NBS1 in hepatocytes before HBV infection significantly decreased viral markers, including cccDNA, while reconstitution reversed the effect. …”

Plasmids information. by Kaitao Zhao (3617825)

“…Results revealed the MRE11–RAD50–NBS1 (MRN) complex as a potential factor. Transiently or stably knockdown of MRE11, RAD50 or NBS1 in hepatocytes before HBV infection significantly decreased viral markers, including cccDNA, while reconstitution reversed the effect. …”

Raw data. by Kaitao Zhao (3617825)

“…Results revealed the MRE11–RAD50–NBS1 (MRN) complex as a potential factor. Transiently or stably knockdown of MRE11, RAD50 or NBS1 in hepatocytes before HBV infection significantly decreased viral markers, including cccDNA, while reconstitution reversed the effect. …”

Table 1_The association between oxidative balance scores and all-cause mortality and cancer-specific mortality in cancer survivors: a retrospective cohort study.doc by Ran He (207626)

“…A similar significant association was found with cancer-specific mortality, while no significant association was noted for CVD mortality. …”

Clinical and epidemiological data of patients. by Mailma Costa de Almeida (22057684)

“…CTG showed a significant reduction in pain within 24 hours in the per-protocol analysis (Log-rank <i><i>p</i></i> = <i><i>0.04</i></i>). …”

Supplementary Material for: SPECKLE TRACKING ECHOCARDIOGRAPHY IN TWIN PREGNANCIES AND THE ROLE OF GLOBAL LONGITUDINAL STRAIN AND PEAK SYSTOLIC STRAIN: A SYSTEMATIC REVIEW AND META-... by Meireson E. (20224101)

“…The global longitudinal strain in the right and left ventricle and the peak systolic strain in the right ventricle of the recipient MCDA twin is significantly decreased compared to the donor MCDA twin. 2D STE assessment was shown feasible and reproducible in MCDA pregnancies. …”

Image1_Kidney outcomes associated with SGLT2 inhibitors compared to other glucose-lowering drugs: a real-world study from China.TIF by Xiang Xiao (44417)

“…Throughout the follow-up period, we observed a significant decrease in the rate of eGFR decline in patients using SGLT2i (4.94 mL/min/1.73 m² per year reduction compared to oGLDs, 95% CI: 4.73–5.15). …”

Image2_Kidney outcomes associated with SGLT2 inhibitors compared to other glucose-lowering drugs: a real-world study from China.TIF by Xiang Xiao (44417)

“…Throughout the follow-up period, we observed a significant decrease in the rate of eGFR decline in patients using SGLT2i (4.94 mL/min/1.73 m² per year reduction compared to oGLDs, 95% CI: 4.73–5.15). …”

Image8_Kidney outcomes associated with SGLT2 inhibitors compared to other glucose-lowering drugs: a real-world study from China.TIF by Xiang Xiao (44417)

“…Throughout the follow-up period, we observed a significant decrease in the rate of eGFR decline in patients using SGLT2i (4.94 mL/min/1.73 m² per year reduction compared to oGLDs, 95% CI: 4.73–5.15). …”

Image5_Kidney outcomes associated with SGLT2 inhibitors compared to other glucose-lowering drugs: a real-world study from China.TIF by Xiang Xiao (44417)

“…Throughout the follow-up period, we observed a significant decrease in the rate of eGFR decline in patients using SGLT2i (4.94 mL/min/1.73 m² per year reduction compared to oGLDs, 95% CI: 4.73–5.15). …”

Image6_Kidney outcomes associated with SGLT2 inhibitors compared to other glucose-lowering drugs: a real-world study from China.TIF by Xiang Xiao (44417)

“…Throughout the follow-up period, we observed a significant decrease in the rate of eGFR decline in patients using SGLT2i (4.94 mL/min/1.73 m² per year reduction compared to oGLDs, 95% CI: 4.73–5.15). …”

Image3_Kidney outcomes associated with SGLT2 inhibitors compared to other glucose-lowering drugs: a real-world study from China.TIF by Xiang Xiao (44417)

“…Throughout the follow-up period, we observed a significant decrease in the rate of eGFR decline in patients using SGLT2i (4.94 mL/min/1.73 m² per year reduction compared to oGLDs, 95% CI: 4.73–5.15). …”